



Correction to: Tadalafil monotherapy in management of chronic prostatitis/chronic pelvic pain syndrome: a randomized double-blind placebo controlled clinical trial

Ahmed M. Tawfik¹ · Mohammed H. Radwan¹ · Mohammed Abdulmonem² · Mohammed Abo-Elenen¹ · Samir A. Elgamal¹ · Mohammed O. Aboufarha¹

Published online: 18 August 2022
© The Author(s) 2022

Correction to: World Journal of Urology
<https://doi.org/10.1007/s00345-022-04074-4>

There is a mistake in the top cells of Table 2 in the original publication of the article. The top cells should be shifted one column to the right to make it inline with the corresponding data. The correct Table 2 is given below:

The original article has been corrected.

The original article can be found online at <https://doi.org/10.1007/s00345-022-04074-4>.

✉ Ahmed M. Tawfik
dr_ahmad_tawfik@yahoo.com

¹ Urology Department, Faculty of Medicine, Tanta University, Tanta, Egypt

² Urology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

Table 2 Baseline and post treatment results in both groups

		Tadalafil group (59 patients)		Control-group (56 patients)	
		Baseline score	6th week score	Baseline score	6th week score
Pain	Range	6–20	3–19	5–20	4–20
	Mean \pm SD	12.14 \pm 3.57	10.42 \pm 3.55 *	12.04 \pm 3.88	11.71 \pm 3.9
	Median	12	10	11.5	11.5
Urinary	Range	2–9	1–8	1–9	1–9
	Mean \pm SD	6.08 \pm 1.53	4.2 \pm 1.72 ^{*,Y}	6.04 \pm 1.62	5.93 \pm 1.73
	Median	6	4	6	6
Qol	Range	3–9	2–9	4–9	3–9
	Mean \pm SD	6.22 \pm 1.76	4.47 \pm 1.64 ^{*,Y}	6.23 \pm 1.25	6.14 \pm 1.46
	Median	6	4	6	6
Total	Range	15–37	9–31	16–34	13–35
	Mean \pm SD	24.21 \pm 5.05	19.1 \pm 5.26 ^{*,Y}	24.3 \pm 4.51	23.79 \pm 5.2
	Median	23	18	24	24
IIEF-5	Range	13–21	16–25	11–21	10–23
	Mean \pm SD	17.6 \pm 2.2	21 \pm 1.8 ^{*,Y}	17.2 \pm 3.04	17.46 \pm 3.56
	Median	17	21	18	18

*: Statistically significant when compared to base line value, paired *t* test ($p < 0.05$)

^Y: Statistically significant when compared to 6th week values, unpaired *t* test, Welch corrected. ($p < 0.05$)

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in

the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.